Zero. The week three prevention arcs closed at once.

TL;DR

• Zero cervical cancer deaths among women aged 20–24 in England, 2020–2024. Counterfactual: ~23 deaths would have been expected without HPV vaccination. Published The Lancet, 18 June 2026.
• The load-bearing variable is age at vaccination. Relative reduction in cervical cancer: 34% at ages 16–18, 62% at 14–16, 87% at 12–13. CIN3 precursor lesions: 97% reduction at 12–13.
• Same 10-day window: WHO confirmed lenacapavir HIV PrEP is now rolling out across nine African countries (Eswatini, Kenya, Lesotho, Mozambique, Nigeria, South Africa, Uganda, Zambia, Zimbabwe). Generic manufacturing licences will drop the per-person cost below $40/year from 2027. India's smoking prevalence has halved this century.
• Uptake, not efficacy, is the gate. England's near-elimination result was delivered by school-based delivery at 12–13 with ~90% coverage. The US sits at ~60%. Parts of Southern and Eastern Europe are below 40%.

Zero

Between 2020 and 2024, no women aged 20 to 24 died of cervical cancer in England.

That is the finding published in The Lancet on 18 June 2026 by Sasieni and Falcaro of Queen Mary University London, drawing on 13.7 million woman-years of follow-up data. The counterfactual — how many deaths would have occurred without the national HPV vaccination programme — is 23 in that one age group over that one five-year window. The wider figure, across all age groups so far reached by the vaccinated cohort, is approximately 200 lives.

This is the first quantification of mortality, not just cancer incidence, attributable to HPV vaccination. Vaccination programmes have been claiming lives-saved projections for two decades. This is the first study that pins a specific mortality number to a specific vaccinated cohort with observational follow-up long enough to matter.

Cervical cancer in one high-income country has effectively been engineered out of one birth cohort. That is not rhetoric. It is what the data now show.

The number that actually does the work

Age at vaccination.

• Ages 16–18: 34% relative reduction in cervical cancer (95% CI 25–41).
• Ages 14–16: 62% reduction (52–71).
• Ages 12–13: 87% reduction (72–94).

For the precursor lesion (CIN3), the corresponding reductions climb further — 39%, 75%, and 97% at ages 12–13.

The mechanism is unglamorous. HPV exposure typically begins at sexual debut. Vaccination before exposure prevents infection. No infection, no cancer. The clinical implication is that vaccination-age policy is the single largest lever any country holds over the ultimate mortality curve.

Countries that offer the vaccine at 12–13 with school-based delivery — England, Scotland, Australia, Rwanda, Portugal — achieve the near-elimination result. Countries that leave it to opportunistic pharmacy or GP-based delivery in older age groups collect a fraction of the same benefit.

The adjacent stories, held against each other

Three items landed in a single 10-day window in late June 2026. Read them side by side:

1. The Lancet HPV mortality result — England, near-elimination in the earliest vaccinated cohort.

2. Lenacapavir rollout in nine African countries — twice-yearly injectable pre-exposure prophylaxis for HIV, ~100% effective in the 2024 PURPOSE-1 and PURPOSE-2 trials. WHO Director-General Tedros confirmed on 6 March that the WHO has supported rollout in Eswatini, Kenya, Lesotho, Mozambique, Nigeria, South Africa, Uganda, Zambia, and Zimbabwe. South Africa launched its national programme in Secunda, Mpumalanga on 15 June 2026. The Gilead voluntary-licensing arrangement with six generic manufacturers, coordinated by the Clinton Health Access Initiative, Unitaid, Wits RHI, and Dr Reddy's, is on track for large-scale generic supply at approximately $40 per person per year from 2027. PEPFAR and the Global Fund have committed to reaching 3 million people by 2028.

3. India's smoking prevalence has halved this century. Positive News round-up 26 June 2026, drawing on Lancet Countdown series data. In a country where smoking-attributable mortality has run close to one million deaths per year, halving prevalence over 25 years is the most consequential single wellness metric shift on the planet.

Three prevention arcs — a cancer, an infection, a chronic-disease driver — closing in one fortnight, each with concrete numbers, each attributable to public health investment made years earlier. That is the shape of an inflection. Not a moment. A shape.

The hype deconstruction, gently

None of this makes the case that the HPV vaccine is a miracle in the retail sense. HPV vaccination effectiveness against cervical cancer mortality is likely not literally 100% — Sasieni and Falcaro say so directly, noting that a small number of deaths may have been missed in the dataset. Herd effects compensate for imperfect individual protection. The 20–24-year-old cohort in the paper was vaccinated with the bivalent Cervarix; current 9-valent products should perform at least as well and possibly better, but that is a projection, not a confirmed result.

The story is not that HPV has been eradicated. The story is that in one country, in one birth cohort, with high uptake and school-based delivery to 12–13-year-olds, cervical cancer has moved from rare cause of death in young women to effectively no cause of death in young women. That is a specific and testable claim. And it has been tested.

The necessary companion deconstruction: this is what an intervention looks like when it lands at 90% uptake before exposure. Every element of that sentence — 90%, before, exposure — is a lever with independent implementation politics.

• United States: HPV coverage plateaued around 60% and dropped during the pandemic. The current mortality curve will diverge from England's.
• Southern and Eastern Europe: coverage below 40% in Poland, Romania, Bulgaria, Greece.
• Sub-Saharan Africa: WHO's endorsement of single-dose HPV regimens (SAGE, 2022) has expanded feasible coverage, but rollout remains uneven. Ethiopia, Rwanda, and Zambia are running credible national programmes; many neighbouring countries are not.
• Australia: pioneered the national HPV programme in 2007 with school-based delivery and ~80% coverage. On the same trajectory the Lancet paper describes, running roughly one to two years behind England.
• Japan: proactive-recommendation withdrawal from 2013–2022 crashed uptake below 1%; the reinstated programme has recovered coverage but with a lost cohort still visible in the mortality data to come.

The stack

For readers watching the HIV story from the Global North: the lenacapavir rollout is the equivalent story on a compressed timeline. Twice-yearly injection, near-total efficacy at ~$40/year at generic scale from 2027, delivery through existing PrEP clinics. The uptake question is the same question in a different guise — whether the delivery system reaches the people at highest risk before exposure.

For readers watching the smoking story: the mechanism in India has been a combination of price (excise), place-of-use restriction (public smoking bans), and hard-hitting graphic warnings on packaging — the WHO MPOWER framework, applied consistently over two decades. No individual behavioural intervention is doing the load-bearing work.

Prevention wins on public-health infrastructure. Not on individual willpower, not on wellness content, not on supplementation. On school nurses with clipboards, community clinics with cold chains, and tax codes that make cigarettes expensive.

What this means for readers

Recommendations are addressed to the general public — patients, parents, and families — with specific passes for readers in other roles.

For parents of pre-adolescents in any country with a national HPV programme:

The age-at-vaccination finding in the Sasieni/Falcaro paper is the number to hold onto. 12–13 is not arbitrary — it is the band where the mortality benefit peaks (87% cancer reduction, 97% CIN3 reduction). Delaying by two years cuts the benefit substantially. If your country's programme offers vaccination at 12–13 through the school system, take the appointment. If it doesn't, ask your GP or paediatrician about the schedule at that age band.

For adults who missed the school-age window:

Catch-up vaccination remains meaningful — approved up to age 26 in most jurisdictions, up to 45 with shared decision-making in the US and Australia. Imperfect protection, still worth doing. The 34% reduction figure applies to catch-up delivery at 16–18; the number decreases with age but does not go to zero.

For anyone under 30 in England, Australia, or comparable countries who was offered the vaccine as a child:

The current national cervical screening schedule still applies. HPV vaccination reduces risk substantially. It does not eliminate the screening rationale. Follow the schedule.

For readers in countries where the national programme has not been implemented or has stalled:

The Australian, English, and Rwandan school-based delivery models are the evidence-backed lever to push for locally. Australian PHAs, MP correspondence, and school-parent-association channels are the mechanism if this matters to you.

For readers at risk of HIV exposure in countries where lenacapavir is now available (South Africa, Kenya, Uganda, Zambia, Zimbabwe, Eswatini, Lesotho, Mozambique, Nigeria):

South Africa's rollout is currently limited to approximately half a million people at 360 clinics in high-incidence areas — supply-constrained until generic manufacturing scales in 2027. Where available, twice-yearly injection removes the daily-adherence burden that has limited oral PrEP uptake among adolescents and young adults.

For readers in the Global North who are not immediately affected by any of this:

The useful take-away is a calibration adjustment. The current wellness attention economy is dominated by longevity supplements, biological-age testing, and biohacking protocols. The wellness gains actually landing in the mortality data this month are the boring ones — school vaccinations, generic HIV prophylaxis, tobacco taxation. Neither category is wrong. Only one of them is doing the heavy lifting.

Uncertainty ledger

• Long-term (>15 year) HPV vaccine protection: presumed on immunological grounds, still being confirmed as vaccinated cohorts age into higher-risk windows (30s and 40s, where cervical cancer incidence peaks).
• 9-valent versus bivalent long-term mortality curve: the 9-valent should outperform the bivalent on the additional oncogenic HPV types it covers; the mortality data are still accruing.
• Single-dose HPV schedules: WHO SAGE endorsed on immunogenicity grounds in 2022; mortality-endpoint confirmation is still forming.
• Lenacapavir real-world uptake beyond the initial 360 South African clinics: unknown. Cost-per-QALY figures depend on generic pricing landing at the projected $40/year.
• Anti-vaccine political pressure in the US, Italy, and pockets of Australia and Central Europe: current coverage figures are the leading indicator. Expect the next decade's mortality curves to diverge between countries that hold uptake and countries that don't.

Bottom Line

For the first time in medical history, a cancer has effectively been engineered out of a birth cohort — in a country that vaccinated 90% of its 12–13-year-olds. The science won. In every country that has not matched England's numbers, the remaining question is not whether the vaccine works. It is whether the country is willing to run the programme that makes it work. Delivered at age 12–13, at scale, through schools, before exposure. Every deviation from that specification is a fraction of the benefit surrendered.

Sources

• Sasieni & Falcaro, The Lancet, 18 June 2026 — HPV vaccination effect on cervical cancer mortality in England — Tier 1
• BBC (17 June 2026); The Guardian (18 June 2026); The Independent (18 June 2026); LA Times (29 June 2026); CIDRAP (25 June 2026) — coverage of Lancet finding — Tier 1
• Gavi / Cancer Research UK briefings (23 June 2026) — HPV vaccination programme impact — Tier 1/2
• World Health Organization — lenacapavir rollout announcement across 9 African countries (6 March 2026); South Africa national programme launch (15 June 2026, Secunda, Mpumalanga) — Tier 1
• PURPOSE-1 and PURPOSE-2 trials (2024) — lenacapavir efficacy for HIV pre-exposure prophylaxis, Science 2024 Breakthrough of the Year — Tier 1
• Gilead Sciences access strategy statement (30 June 2026) — voluntary licensing and generic pricing framework — Tier 2, source disclosure noted
• Spotlight NSP (South Africa) — 3 June 2026 briefing on lenacapavir rollout — Tier 2
• NPR — lenacapavir Eswatini/Zambia deployment coverage (November 2025) — Tier 2
• Positive News round-up (26 June 2026), citing Lancet Countdown series — India smoking prevalence — Tier 3, contextual
• The Pharmaceutical Journal (26 June 2026) — HPV, HIV prevention, and Type 1 diabetes delay round-up — Tier 2